

Evusheld for pre-exposure prophylaxis of COVID-19 Position Statement

Evusheld is not available to NHS patients treated in North Central London NHS hospitals at the current time.

This position complies with current advice from the UK Government and will be reviewed immediately upon receipt of new information.

Multiple patient representative organisations launched a joint campaign called the 'Forgotten 500,000' in October 2022. The campaign is in response to the UK Government's decision to not procure Evusheld (tixagevimab-cilgavimab) in advance of the planned review by the National Institute of Health and Care Excellent (NICE). The government were advised by an expert panel, who undertook multiple detailed reviews of the available evidence-base.

A detailed explanation as to why the UK Government made their decision, including more detail about the expert panel (called RAPID C-19) and why the current evidence base is considered insufficient against current and emerging COVID-19 variants, is available below:

<https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups/decision-on-evusheld-as-a-covid-19-treatment>

In line with Government advice, NHS hospitals do not offer Evusheld to NHS patients at the current time.

The expected publication date for NICE technology appraisal guidance is 31st May 2023 (correct at time of writing):

<https://www.nice.org.uk/guidance/indevelopment/gid-ta11102>

Patients who choose to pursue Evusheld outside the NHS may decide to do so via a private health provider. Evusheld is given by a healthcare professional as two injections into a muscle (usually one injection into each buttock) followed by a 1 hour observation period. This administration will need to take place in a private healthcare setting. Details about accessing Evusheld privately is available via Blood Cancer UK website:

<https://bloodcancer.org.uk/news/evusheld-available-uk-buy-privately/>

Groups / Individuals who have overseen the development of this guidance:	UCLH and RFL formulary teams
Groups which were consulted and have given approval:	NCL Joint Formulary Committee
File name:	Position Statement – Evusheld for pre-exposure prophylaxis of COVID-19
Version number:	V1
Available on:	https://www.ncl-mon.nhs.uk/
Disseminated to:	NCL Formulary Pharmacists and Commissioners
NCL Joint Formulary Committee Approval date:	17 November 2022
Review date:	31 May 2023